Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union

SOUTH SAN FRANCISCO, Calif., March 23, 2018 -- (Healthcare Sales & Marketing Network) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ... Biopharmaceuticals, Regulatory Portola Pharmaceuticals, Bevyxxa, betrixaban, venous thromboembolism
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news